Newsroom 2006
Attention Business/Financial Editors:
Neurochem reports results for fourth quarter and fiscal year 2005
LAVAL, Feb. 23 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM)
reported results for the fourth quarter and fiscal year ended December 31,
2005. The Company reported a net loss of $15.6 million ($0.42 per share) for
the quarter, similar to the net loss of $15.4 million ($0.51 per share)
recorded in the fourth quarter of 2004. Research and development expenses
(R&D) increased slightly during the fourth quarter of 2005 to $11.7 million
from $10.6 million for the same period last year. For the full year, Neurochem
reported a net loss of $72.4 million, compared to $52.4 million for fiscal
2004, due to higher R&D expenses of $50.5 million for 2005 compared to
$31.0 million for 2004. The increase in R&D expenses is mainly related to drug
development activities including tramiprosate's (Alzhemed(TM)) ongoing North
American and European Phase III clinical trials. During the quarter, the
Company advanced the ongoing Fibrillex(TM) Phase II/III open-label extension
study and the submission of its "rolling" New Drug Application (NDA) for
eprodisate (Fibrillex(TM)) for the treatment of Amyloid A amyloidosis with the
U.S. Food and Drug Administration (FDA). The NDA submission was completed in
February 2006.
At the end of the quarter, the Company reported cash, cash equivalents
and marketable securities of $71.1 million, up from $29.2 million at December
31, 2004. The increase is primarily due to net proceeds received from the
issue of additional share capital in March 2005, from the exercise of a
warrant in July 2005 by Picchio Pharma Inc., revenues received from the
collaboration with Centocor, Inc., and from a sale and leaseback transaction
regarding its facilities and campus located in Laval for net cash proceeds
after debt repayment of $22 million in November 2005. On February 16, 2006,
Neurochem received additional proceeds of approximately $9.4 million from the
exercise by a subsidiary of Picchio Pharma Inc. of a warrant, otherwise
scheduled to expire on February 18, 2006.
"In fiscal 2005, Neurochem has accomplished what it set out to do and has
delivered on key milestones," said Dr. Francesco Bellini, Neurochem's
Chairman, President and CEO. "Neurochem completed its NDA submission to the
U.S. Food and Drug Administration seeking marketing approval for
Fibrillex(TM). For Alzhemed(TM), the Company completed patient recruitment for
its ongoing Phase III clinical trial in North America. At the present time,
more than 400 patients have already completed 12 months of the 18-month
Phase III clinical trial. Patient recruitment is on schedule for the
Alzhemed(TM) Phase III clinical trial in Europe, where the trial is proceeding
well, with over 100 patients already enrolled. With this progress and
Neurochem's financial position, the Company expects to continue its steady
advance towards becoming a solid biopharmaceutical company," he concluded.
Conference Call
Neurochem will host a conference call Friday, February 24, 2006, at
8:30 A.M. Eastern Time. The telephone numbers to access the conference call
are 1-416-695-6370 or 1-877-461-2815. A replay of the call will be available
until Friday, March 3, 2006. The telephone numbers to access the replay of the
call are 1-416-695-5275 or 1-888-509-0081. Please mention that you are calling
for the Neurochem conference replay.
Consolidated Financial Results Highlights
The following discussion and analysis should be read in conjunction with
the audited consolidated financial statements for the year ended December 31,
2005, which have been prepared in accordance with Canadian generally accepted
accounting principles. All dollar figures are Canadian dollars, unless
specified otherwise.
Results of operations
For the three-month period ended December 31, 2005, the net loss amounted
to $15,628,000 ($0.42 per share), compared to $15,388,000 ($0.51 per share)
for the corresponding period last year. For the year ended December 31, 2005,
the net loss amounted to $72,366,000 ($2.06 per share), compared to
$52,399,000 ($1.74 per share) for the same period last year.
Revenue from collaboration agreement amounted to $607,000 for the current
quarter ($3,384,000 for the year), compared to $132,000 for the same period
last year ($132,000 for the year). This revenue is earned under the agreement
with Centocor, Inc. (Centocor) in respect of eprodisate (Fibrillex(TM)), an
oral investigational product candidate for the treatment of Amyloid A (AA)
amyloidosis. Revenue recognized is in respect of the non-refundable upfront
payment received from Centocor, which is being amortized over the estimated
period through to the anticipated regulatory approval date of the
investigational product candidate. The estimated period is subject to change
based on additional information that the Company may receive periodically. The
other portion of the upfront payment received from Centocor (US$6,000,000) has
been classified as long term deferred revenues and is not being amortized as
earned revenues given that it is refundable in the event that the Company
receives a non-approvable letter issued by the US Food and Drug Administration
(FDA). The Company anticipates a decision by the FDA regarding Fibrillex(TM)
during 2006.
Reimbursable costs revenue amounted to $230,000 for the current quarter
($1,057,000 for the year), compared to $195,000 for the same period last year
($195,000 for the year) and consists of costs reimbursable by Centocor in
respect of Fibrillex(TM) related activities. The Company earns no margin on
these reimbursable costs.
Research and development expenses, before research tax credits and
grants, amounted to $11,688,000 for the current quarter ($50,495,000 for the
year), compared to $10,612,000 for the same period last year ($30,957,000 for
the year). The increase for the year is primarily due to expenses incurred in
relation to the development of tramiprosate (Alzhemed(TM)) for the ongoing
Phase III clinical trials in North America and Europe. For the year ended
December 31, 2005, research and development expenses also included costs
incurred to support the on-going Fibrillex(TM) Phase II/III open-label
extension study, the Alzhemed(TM) Phase II open-label extension study, as well
as on-going drug discovery programs. Alzhemed(TM) is the Company's
investigational product candidate for the treatment of Alzheimer's disease
(AD). In 2005, the Company completed the enrolment of 1052 patients with mild-
to-moderate AD for its North American Phase III clinical trial for
Alzhemed(TM), designed to demonstrate the safety, efficacy and disease-
modifying potential of the product candidate in the treatment of AD. The study
duration is 18 months and the trial is being conducted in close to 70 clinical
centers in the US and in Canada. The Company also launched its Phase III
clinical trial in Europe in September 2005 and enrolled its first patient in
November. The European Phase III clinical trial will investigate the safety,
efficacy and disease-modifying potential of Alzhemed(TM), with 930 mild-to-
moderate AD patients expected to participate. The trial will be conducted at
approximately 70 centers in ten European countries, and the study duration
will be 18 months. Furthermore, the Company completed, under the Continuous
Marketing Application (CMA) Pilot 1 program, the submission of a "rolling" New
Drug Application (NDA) to the FDA seeking marketing approval for its
investigational product candidate, Fibrillex(TM), for the treatment of AA
amyloidosis. The Company announced on February 13, 2006 that it completed the
submission of the NDA, with additional data from the open-label extension
expected to be filed shortly thereafter. The FDA agreed in June 2005 to file
and review the NDA. The Company expects research and development expenses to
increase in the future as product candidates progress through the different
stages of clinical development and as the Company continues to invest in
product research and development.
Research tax credits amounted to $565,000 this quarter ($3,190,000 for
the year), compared to $541,000 for the corresponding period last year
($1,463,000 for the year). Research tax credits represent refundable tax
credits earned under the Quebec Scientific Research and Experimental
Development Program. The increase for the year is mainly attributable to
increased research and development expenses eligible for tax credits as well
as tax credits of $1,333,000 recorded during the year and earned with respect
to current and prior years' eligible research and development taxable benefits
on stock options. Management determined that these credits were reasonably
assured of realization based on a recent court ruling.
Research grants amounted to $1,164,000 for the current quarter
($1,203,000 for the year), compared to $9,000 for the same quarter last year
($336,000 for the year). The increase is due to the final contribution
received by the Company during the current quarter under the Technology
Partnerships Canada (TPC) Program for the development of Alzhemed(TM).
General and administrative expenses totaled $4,393,000 for the current
quarter ($22,212,000 for the year), compared to $4,451,000 for the same
quarter last year ($17,953,000 for the year). The increase for the year is
primarily attributable to higher legal fees in connection with the dispute
with Immtech International, Inc. (Immtech) and to the expansion of the
corporate infrastructure to support growth. The expenses in relation to the
expansion of the corporate infrastructure include an increase in operating
costs related to the facilities acquired in May 2004 and other corporate
agreements and matters.
Reimbursable costs amounted to $230,000 for the current quarter
($1,057,000 for the year), compared to $195,000 for the same period last year
($195,000 for the year) and consist of costs incurred on behalf of Centocor in
respect of Fibrillex(TM) related activities and reimbursable by Centocor.
Stock-based compensation amounted to $865,000 for the current quarter
($4,795,000 for the year), compared to $709,000 for the corresponding quarter
last year ($4,038,000 for the year). This expense relates to employee and
director stock options, and stock-based incentives, whereby compensation cost
is measured at fair value at the date of grant and is expensed over the
award's vesting period. For the year ended December 31, 2005, stock-based
compensation includes $1,441,000 relating to 140,000 common shares to be
issued to the Chairman, President and Chief Executive Officer, pursuant to an
agreement dated December 1, 2004.
Special charges amounted to $1,676,000 for the year ended December 31,
2004, and were related to the relocation to facilities acquired from Shire
BioChem Inc. in May 2004. An adjustment in the amount of $409,000 was recorded
in the fourth quarter of 2004 to reflect an agreement signed during that
quarter to sublease the former premises. No such charges were incurred in
2005.
Depreciation, amortization and write-off of patents amounted to
$1,413,000 for the current quarter ($3,189,000 for the year), compared to
$592,000 for the same quarter last year ($2,046,000 for the year). Expenses
for the quarter and year ended December 31, 2005, include the write-off of
patent costs of $853,000 in relation to non-core technology patents
responsibility for which reverted to Parteq Research & Development
Innovations. The increase for the year also reflects the depreciation and
amortization associated with the acquisition during the past year of
additional property and equipment, including the facilities acquired in the
second quarter of 2004, and the additions to patent costs.
Interest and bank charges amounted to $82,000 for the current quarter
($462,000 for the year), compared to $126,000 for the same quarter last year
($277,000 for the year). The increase for the year is due to interest expense
on the $10,500,000 revolving decreasing term credit facility entered into by
the Company to finance the acquisition of the facilities in May 2004. The
decrease for the quarter is attributable to the reimbursement of the term
credit facility in November 2005.
Interest income amounted to $607,000 for the current quarter ($2,082,000
for the year), compared to $208,000 for the same quarter last year ($1,030,000
for the year). The increase results from higher average cash balances in the
current periods compared to the same periods last year, due to proceeds
received from the public offering, the exercise of a warrant and the sale
leaseback transaction, as well as higher interest rates during 2005. Refer to
the Liquidity and Capital Resources section for details on the public
offering, the sale leaseback transaction and the exercise of a warrant.
Foreign exchange gain amounted to $255,000 for the current quarter
($187,000 for the year), compared to a loss of $401,000 for the same quarter
last year (gain of $1,298,000 for the year). Foreign exchange gains or losses
arise on the movement in foreign exchange rates related to the Company's net
monetary assets held in foreign currencies, primarily US dollars. The Company
maintains a significant US dollar position to serve as a natural hedge of
exchange rate fluctuations with respect to planned US dollar denominated
research and development expenditures primarily relating to its Phase III
clinical programs. Foreign exchange gains recorded for the year ended December
31, 2004, were primarily attributable to a gain realized during the year on
the conversion of US dollars into Canadian dollars.
Other income amounted to $297,000 for the current quarter ($935,000 for
the year), compared to $204,000 for the same period last year ($289,000 for
the year). Other income consists of non-operating revenue, primarily rental
revenue.
Variable interest entities
On January 1, 2005, the Company adopted the recommendations of the CICA
Accounting Guideline 15 - Consolidation of Variable Interest Entities (VIE).
This guideline requires the Company to identify VIEs in which it has an
interest, to determine whether it is the primary beneficiary of such entities
and, if so, to consolidate the VIEs. The implementation of AcG-15 resulted in
the consolidation of the Company's interest in a holding company that owns
Innodia Inc. shares, starting January 1, 2005. The effect of the
implementation of this accounting guideline was to adjust the net carrying
value of the long-term investment and the opening deficit by $2,501,000 at
January 1, 2005. The revised carrying amounts of the long-term investment and
non-controlling interest at January 1, 2005, were $3,359,000 and $1,439,000,
respectively. The implementation of this accounting guideline resulted in the
consolidation in the current quarter of a share of loss in a company subject
to significant influence of $971,000 ($3,124,000 for the year) and non-
controlling interest of $289,000 ($930,000 for the year), in the Consolidated
Statement of Operations.
Litigation
In connection with an agreement concluded in 2002, Immtech brought claims
against the Company in legal proceedings filed on August 12, 2003, with the
Federal District Court for the Southern District of New York, U.S.A. The
dispute is now before an arbitral tribunal convened in accordance with the
rules of the International Court of Arbitration. A hearing before the arbitral
tribunal was held in mid-September 2005. Since the conclusion of the hearing,
the parties have filed with the tribunal their respective Post-Evidentiary
Hearing Briefs and their respective replies thereto. In early January 2006,
responding to a formal request from the arbitral tribunal made on December 27,
2005, the parties to the proceedings submitted their respective summaries of
their attorney fees and costs to which they believe they would be entitled if
they were to prevail in the arbitration. Since then there has been no clear
indication of when the arbitral tribunal will issue its award or decision.
On August 5, 2005, Immtech filed SEC Form 10-Q in relation to its
quarterly report for the period ended June 30, 2005. In that form, Immtech
stated having filed expert reports which set forth a range of monetary damages
based on different scenarios of between US$14 million and US$50 million,
without regard to punitive damages. The Company counterclaimed damages which,
to date, it has estimated at no less than US$3.5 million, which includes an
estimated valuation for equitable relief. The outcome of this matter and the
amount of loss, if any, cannot reasonably be estimated. Accordingly, no
provision for possible loss has been recorded by the Company in connection
with this matter. There can be no assurance that the Company will prevail in
this dispute. The Company has, and will continue to, vigorously defend itself
against claims brought by Immtech.
Liquidity and capital resources
As at December 31, 2005, the Company had available cash, cash equivalents
and marketable securities of $71,091,000, compared to $29,173,000 at December
31, 2004. The increase is primarily due to proceeds received from the issue of
additional share capital in March 2005, from the exercise of a warrant in July
2005, from the sale and leaseback transaction in November 2005, as well as
revenues received from the collaboration with Centocor, Inc., net of funds
used in operations, investing activities and for long-term debt repayment. The
Company believes that its available cash resources and other sources of funds
should be sufficient to finance the Company's operations for the next twelve
months.
On March 9, 2005, the Company completed a public offering of its common
shares in the US and in Canada. The Company issued four million common shares
at a price of US$15.30 per share. Total proceeds from the offering were
$74,495,000 (US$61,200,000) and the issue costs totaled $4,955,000. Of the
original net amount raised, $13,868,000 has yet to be spent as of December 31,
2005; the use of proceeds continues to conform in all material respects with
the expectations set forth in the prospectus. Certain funds raised from the
share issuance were denominated in US dollars. The Company maintains a
significant US dollar position to serve as a natural hedge of exchange rate
fluctuations with respect to planned US dollar denominated research and
development expenditures primarily relating to its Phase III clinical
programs.
On July 25, 2005, a subsidiary of Picchio Pharma Inc. (Picchio Pharma)
exercised a warrant, issued pursuant to a July 2002 private placement that was
otherwise scheduled to expire on that date, generating total proceeds to the
Company of $8,764,000 and resulting in the issuance of 2,800,000 common shares
from treasury.
On November 17, 2005, the Company completed a sale and leaseback
transaction in respect of its facilities and campus located in Laval, Quebec,
for a sale price of $32,000,000. The transaction generated a net gain of
$21,358,000. For accounting purposes, the net gain is deferred and amortized
over the period of the lease. The Company has leased the facilities for a
period of 15 years, with an option to buy it back. Of the proceeds,
$9.8 million was used to repay the long-term debt contracted in 2004 to
finance the acquisition of the facilities from Shire BioChem Inc.
As at January 31, 2006, the Company had 37,442,249 common shares
outstanding, 220,000 common shares issuable to the Chief Executive Officer
upon the achievement of specified performance targets, 2,288,788 options
granted under the stock option plan and a warrant outstanding to purchase
1,200,000 common shares.
On February 16, 2006, Picchio Pharma, the company's largest shareholder,
exercised the warrant previously issued pursuant to a February 2003 private
placement, generating total proceeds to the Company of $9,372,000 and
resulting in the issuance of 1,200,000 common shares from treasury.
Neurochem Inc.
Consolidated Financial Information(1)
(in thousands of Canadian dollars, except per share data)
Three-month period ended Year ended
December 31 December 31
-------------------------------------------------
Consolidated Statements
of Operations 2005 2004 2005 2004
-------------------------------------------------------------------------
-------------------------------------------------------------------------
(unaudited) (unaudited) (audited) (audited)
Revenues:
Collaboration agreement $607 $132 $3,384 $132
Reimbursable costs 230 195 1,057 195
-------------------------------------------------------------------------
837 327 4,441 327
-------------------------------------------------------------------------
Expenses:
Research and development 11,688 10,612 50,495 30,957
Research tax credits (565) (541) (3,190) (1,463)
Research grants (1,164) (9) (1,203) (336)
General and administrative 4,393 4,451 22,212 17,953
Reimbursable costs 230 195 1,057 195
Stock-based compensation 865 709 4,795 4,038
Special charges - (409) - 1,676
Depreciation, amortization
and write-off of patents 1,413 592 3,189 2,046
Interest and bank charges 82 126 462 277
-------------------------------------------------------------------------
16,942 15,726 77,817 55,343
-------------------------------------------------------------------------
Net loss before
undernoted items: (16,105) (15,399) (73,376) (55,016)
Interest income 607 208 2,082 1,030
Foreign exchange gain (loss) 255 (401) 187 1,298
Other income 297 204 935 289
Share of loss in a company
subject to significant
influence (971) - (3,124) -
Non-controlling interest 289 - 930 -
-------------------------------------------------------------------------
Net loss ($15,628) ($15,388) ($72,366) ($52,399)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Net loss per share:
Basic ($0.42) ($0.51) ($2.06) ($1.74)
Diluted ($0.42) ($0.51) ($2.06) ($1.74)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted average number
of common shares
outstanding:
Basic 37,386,296 30,314,108 35,104,342 30,156,194
Diluted 37,905,241 33,944,415 36,485,971 34,545,199
-------------------------------------------------------------------------
-------------------------------------------------------------------------
At At
December 31 December 31
Consolidated Balance Sheets 2005 2004
-------------------------------------------------------------------------
-------------------------------------------------------------------------
(audited) (audited)
Cash, cash equivalents and marketable securities $71,091 $29,173
Other current assets 13,298 20,410
-------------------------------------------------------------------------
Total current assets 84,389 49,583
Capital assets 10,327 21,083
Other long-term assets 2,230 5,782
-------------------------------------------------------------------------
Total assets $96,946 $76,448
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Current liabilities $17,420 $16,406
Deferred revenue 8,779 9,772
Deferred gain on sale of property 19,759 -
Long-term accrued liabilities 207 126
Long-term debt - 9,450
Non-controlling interest 509 -
Shareholders' equity 50,272 40,694
-------------------------------------------------------------------------
Total liabilities and shareholders' equity $96,946 $76,448
-------------------------------------------------------------------------
-------------------------------------------------------------------------
(1) Condensed from the Company's consolidated financial statements.
About Neurochem
Neurochem is focused on the development and commercialization of
innovative therapeutics to address critical unmet medical needs. Eprodisate
(Fibrillex(TM)) is designated as an orphan drug, is a Fast Track product
candidate and is also part of FDA Continuous Marketing Application Pilot 1 and
Pilot 2 programs. The Phase II/III clinical trial of Fibrillex(TM) for the
treatment of AA amyloidosis was concluded in April 2005. The Company has
completed its submission of a New Drug Application for Fibrillex(TM) that the
FDA agreed in June 2005 to file and review. Tramiprosate (Alzhemed(TM)), for
the treatment of Alzheimer's disease, is currently in Phase III clinical
trials in both North America and Europe and tramiprosate (Cerebril(TM)), for
the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy,
has completed a Phase IIa clinical trial.
To Contact Neurochem
For additional information on Neurochem and its drug development
programs, please call the North American toll-free number 1-877-680-4500 or
visit our Web Site at: www.neurochem.com.
Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Neurochem's
control. Such risks include but are not limited to: the impact of general
economic conditions, general conditions in the pharmaceutical industry,
changes in the regulatory environment in the jurisdictions in which Neurochem
does business, stock market volatility, fluctuations in costs, and changes to
the competitive environment due to consolidation, as well as other risks
disclosed in public filings of Neurochem. Consequently, actual future results
may differ materially from the anticipated results expressed in the forward-
looking statements. The reader should not place undue reliance, if any, on the
forward-looking statements included in this news release. These statements
speak only as of the date made and Neurochem is under no obligation and
disavows any intention to update or revise such statements as a result of any
event, circumstances or otherwise. Please see the Annual Information Form for
further risk factors that might affect the Company and its business.
For further information: please contact: Lise Hébert, Ph.D., Vice
President, Corporate Communications, (450) 680-4570, lhebert@neurochem.com
